Cinobufacini injection suppresses the proliferation of human osteosarcoma cells by inhibiting PIN1-YAP/TAZ signaling pathway

• Published in: Frontiers in pharmacology 2023-03, Vol.14, p.1081363-1081363
• Main Authors: Chen, Yuru, Wang, Yanyan, Zhai, Yu, Yuan, Ye, Wang, Junhong, Jin, Yajing, Dang, Lingling, Song, Liming, Chen, Changbao, Wang, Yu
• Format: Article
• Language: English
• Subjects: cinobufacini injection; osteosarcoma; Pharmacology; PIN1; TAZ; YAP
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2023.1081363

Cinobufacini injection (CI), an aqueous extract of , is clinically used for cancer therapy in China, but its molecular mechanism for the treatment of osteosarcoma (OS) remains unclear. We constructed U2OS ectopic subcutaneous tumor model to verify the anti-OS effect of CI . Meanwhile, cell proliferation of U2OS and MG63 cells was monitored using the CCK-8 assay, colony formation and morphological changes. Cell cycle arrest and apoptosis were detected by flow cytometry and western blot, which showed that CI significantly inhibited proliferation, induced cell cycle arrest and apoptosis in human OS cells. The further RNA-seq results identified that the Hippo signaling pathway was involved in the anti-OS effect of CI. YAP/TAZ are two major components of the Hippo pathway in breast cancer and are positively regulated by prolyl isomerase PIN1, we assessed their role in OS using both clinicopathological sections and western blots. CI also inhibited PIN1 enzyme activity in a dose-dependent manner, which resulted in impaired PIN1, YAP, and TAZ expression and . Additionally, 15 potential compounds of CI were found to occupy the PIN1 kinase domain and inhibit its activity. In summary, CI plays an anti-OS role by down-regulating the PIN1-YAP/TAZ pathway.